€63.99
This product ships to the EU, the US and Canada
Looking for Stenabolic for sale? (SR9009) at our store, you can easily buy Stenabolic online. Stenabolic is a novel agonist Rev-ErbA (receptor) and has shown to increase endurance in clinical research.
| Synonyms | Stenabolic, SR9009 |
| Concentration | 20mg per ml |
| Solvent | USP Grade Polyethylene Glycol 400 |
| Molar Mass | 437.94026 g·mol−1 |
| CAS | 1379686-30-2 |
| Chemical Formula | C20H24ClN3O4S |
This product is for laboratory research purposes only and is not approved by the FDA for human use. Stenabolic is NOT a dietary supplement. Any information about its use in this product description refers to clinical research only. By ordering from this site, you agree to our terms of service.
SR9009 commonly known as Stenabolic is an agonist of the Rev-ErbA protein which can be found in different parts of the body such as the liver and the skeletomuscular system. A number of studies have shown Stenabolic's effects on regulating circadian rhythms, acting on fat-storing cells, and influencing lipid and glucose metabolism in the liver tissue. Even though SR9009 is not considered to be a selective androgen receptor modulator (SARM) per se, it also binds to Rev-ErBA resulting in multiple similar effects.
SR9009 has demonstrated several effects in test subjects, these are: regulation of circadian rhythm and sleep patterns [1], weight loss [1], enhanced endurance [2], increased resting metabolic rate [2] , cardioprotection [3], lowered cholesterol levels, lowered bodily inflammation, and arterial Plaque management. In addition to that SR9009 has shown potential in conditions such as heart failure, COPD (chronic obstructive pulmonary disease), and metabolic syndrome [2].
By choosing to buy SARMs at our store Sarmful.com you are investing in the highest quality ingredients, that means minimum 98% (and often higher) pure compounds tested and certified by accredited US third party labs- visit out tests page for more info.
More benefits:
Stenabolic has a long and storied history, dating back to the early 2000s when it was developed by Professor Thomas Burris of the Scripps Research Institute. It was initially created as a treatment for seniors with age-related muscle loss. Stenabolic aimed to be a synthetic drug that was created in the laboratory in an effort to specifically target and activate the receptors located in muscle tissue.
Stenabolic is a SARM that binds to Rev-ERBα, which influences the body’s metabolic activity. When bound, Stenabolic increases the number of mitochondria in the cells.
Synthetically produced REV-ERB ligands have been demonstrated to have an effect and in essence change the circadian behavior in mice and to change the circadian pattern of core clock gene expression in the hypothalamus area of the brain. This was also observed in a variety of metabolic genes present in the liver tissue, skeletal muscle, and adipose tissues, resulting in an increase in energy expenditure possibilities[1].
When a REV-ERB agonist treatment was administered to diet-induced obese mice, the obesity level decreased as fat mass was lowered, and dyslipidemia and hyperglycemia were improved. These outcomes show that synthetically produced REV-ERB ligands that target the circadian rhythm might be beneficial for treating both sleep problems and metabolic illnesses.[1]
SR9009 administered to mice resulted in them being able to run longer distances and for longer periods than normal mice [2]. Overexpression of Rev-erb-α in vitro has been shown to boost the amount of mitochondria and better its respiratory capacity. In addition, overexpression or pharmacological activation of Rev-erb-α in vivo tests resulted in an increased exercise capacity- resulting in better endurance. This suggests that Rev-erb-α may one day be used as a pharmacological target to increase muscle oxidative function by regulating the gene networks [2].
A study on mice low on REV-ERB demonstrated significant cardiac myopathy after transverse aortic constriction compared to the wild-type control mice group, indicating the significance of REV-ERB in protecting the heart from pressure overload. Interestingly enough, Stenabolic was also able to provide cardioprotective effects in REV-ERBα/β cardiac-specific double knockout mice (cDKO) mice.
Also, when administered at peak or trough points of REV-ERB expression, Stenabolic had similar levels of cardioprotection, implying that possibly some cardioprotective effects exist outside of REV-ERB. These results further demonstrate that deletion of REV-ERB accelerates negative cardiac remodeling in response to pressure overload and illustrates the independent cardio-protective aspect of Stenabolic with regard to pressure overload [3].
Another study conducted in vitro showed that pharmacological activation of Rev-Erbα with Stenabolic can reduce the inflammatory body response in lung injury by suppressing TLR4-induced NF-κB activation. SR9009 usage was useful in providing positive effects on the metabolism, as it could ameliorate acidosis and hypoxemia by lowering the arterial PaCO2 and improving arterial PaO2, SO2, HCO3 –, lactic acid concentration levels, and blood PH levels. These results show that Stenabolic can reduce sepsis-induced lung injury and suggest targeting Rev-Erbα may be a promising strategy for preventing and managing acute lung injury [4].
A different study dealing with investigating the anti-tumor effects of SR9009 in the lungs demonstrated that SR9009 is especially bad for both chemo-sensitive and chemo-resistant small cell Lung cancer cells. REV-ERBα was shown to be involved in the antitumor effect of Stenabolic. Also, the core autophagy gene Atg5 was demonstrated as a direct downstream target of REV-ERBα, which was suppressed by the REV-ERB agonist. The interaction between REV-ERBα and this autophagy gene prevented autophagy activity, thereby leading to Stenabolic cytotoxicity in SCLC cells [5].
LAst but not least, one study demonstrated that the administration of the REV-ERBα agonist Stenabolic has been shown to have an effect on energy homeostasis in animals [6]. This study on goldfish showed that SR9009 inhibited feeding and decreased body weight and length gain. In addition, the abundance of ghrelin mRNA was lowered in the intestine while that of leptin-aI increased in the liver tissue. SR9009 also was shown to decrease plasma glucose levels coupled with higher glycolysis and lower gluconeogenesis rate in the liver, while lipid levels and lipogenic enzyme activities were reduced too. Interestingly, the energy expenditure by locomotor activity remained unaffected. These results point towards REV-ERBα activation from Stenabolic promotes a negative energy balance by reducing energetic inputs and regulating lipid and glucose metabolism [6].
Some research subjects administered Stenabolic have anecdotally shown side effects such as headache, fatigue, or nausea. These side effects have tended to be mild and disappear over time on their own.
Cardarine and Stenabolic are different in a few ways. Cardarine has a much longer half-life than Stenabolic. It is disputed whether Cardarine has a safer profile than Stenabolic, more research is needed to confirm what the answer is.
There is no clear answer as to whether Stenabolic may promote cancer or not. Some research suggests that it might be a bad compound and could lead to the development of cancer, while other research suggests that it does not. Overall, it is inconclusive and more trials need to occur before there is a definitive answer on whether the compound causes cancerous behavior.
The half-life of Stenabolic is about 4-5 hours, which means that it requires administration multiple times per day.
Stenabolic is sold as a medical research compound and is available online through specialty retailers that sell SARMs.
There are many counterfeit and fraudulent Stenabolic knock-offs on the market.
Stenabolic Chemical Structure
SARMs should only be used under the direct supervision and direction of a trained and licensed medical doctor or a designated research authority. Sarmful strongly discourages the use of SARMs for performance enhancement in fields of various sports such as bodybuilding and achievement sports, etc.
S4 is an investigational compound still undergoing research and NOT yet FDA approved, nor it is a dietary supplement. Sarmful is solely a research chemical supplier specializing in sourcing and quality control. We are not medical doctors. Sarmful discourages strongly against “bro science” and peer consensus when making decisions about human health.
We do not encourage or condone consumer use of SARMs products, they are for research purposes only.
€63.99
See The Latest Lab Test
